BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 28425245)

  • 21. Risk for K-ras gene mutations in smoking-induced lung cancer is associated with cytochrome P4501A1 and glutathione S-transferase micro1 polymorphisms.
    Noda N; Matsuzoe D; Konno T; Kawahara K; Yamashita Y; Shirakusa T
    Oncol Rep; 2004 Oct; 12(4):773-9. PubMed ID: 15375499
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of CYP1A1, GSTT1 and GSTM1 polymorphisms on the risk of lung cancer: a case-control study.
    Atinkaya C; Taspinar M; Sakiragaoglu O; Oz G; Yazici U; Oztuna D; Tastepe I; Sunguroglu A
    Hum Exp Toxicol; 2012 Oct; 31(10):1074-80. PubMed ID: 22893352
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CYP1A1 Ile462Val and MPO G-463A interact to increase risk of adenocarcinoma but not squamous cell carcinoma of the lung.
    Larsen JE; Colosimo ML; Yang IA; Bowman R; Zimmerman PV; Fong KM
    Carcinogenesis; 2006 Mar; 27(3):525-32. PubMed ID: 16195240
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Polymorphisms of cytochrome P450 1A1, glutathione S-transferase class mu, and tumour protein p53 genes and the risk of developing gallbladder cancer in Japanese.
    Tsuchiya Y; Kiyohara C; Sato T; Nakamura K; Kimura A; Yamamoto M
    Clin Biochem; 2007 Aug; 40(12):881-6. PubMed ID: 17531965
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genetic polymorphisms in GST genes and survival of colorectal cancer patients treated with chemotherapy.
    Funke S; Timofeeva M; Risch A; Hoffmeister M; Stegmaier C; Seiler CM; Brenner H; Chang-Claude J
    Pharmacogenomics; 2010 Jan; 11(1):33-41. PubMed ID: 20017670
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effect of CYP1A1 and GSTM1 gene polymorphisms in bladder cancer development in a Turkish population.
    Öztürk T; Kahraman ÖT; Toptaş B; Kisakesen Hİ; Çakalir C; Verim L; Öztürk O; İsbir T
    In Vivo; 2011; 25(4):663-8. PubMed ID: 21709011
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Glutathione-S-transferase P1 isoenzyme polymorphisms, platinum-based chemotherapy, and non-small cell lung cancer.
    Booton R; Ward T; Heighway J; Ashcroft L; Morris J; Thatcher N
    J Thorac Oncol; 2006 Sep; 1(7):679-83. PubMed ID: 17409936
    [TBL] [Abstract][Full Text] [Related]  

  • 28. GSTM1, GSTT1, and GSTP1 polymorphism and lung cancer risk in relation to tobacco smoking.
    Schneider J; Bernges U; Philipp M; Woitowitz HJ
    Cancer Lett; 2004 May; 208(1):65-74. PubMed ID: 15105047
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Increased risk of non-small cell lung cancer and frequency of somatic TP53 gene mutations in Pro72 carriers of TP53 Arg72Pro polymorphism.
    Szymanowska A; Jassem E; Dziadziuszko R; Borg A; Limon J; Kobierska-Gulida G; Rzyman W; Jassem J
    Lung Cancer; 2006 Apr; 52(1):9-14. PubMed ID: 16499995
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of GSTM1 (Null/Present), GSTP1 (Ile105Val) and P53 (Arg72Pro) genetic polymorphisms and the risk of breast cancer: a case control study from South India.
    Samson M; Swaminathan R; Rama R; Sridevi V; Nancy KN; Rajkumar T
    Asian Pac J Cancer Prev; 2007; 8(2):253-7. PubMed ID: 17696741
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Association between genetic polymorphism of metabolizing enzymes and DNA repairing enzymes and the susceptibility of lung cancer in Henan population].
    Wang N; Wu Y; Zhou X; Wu Y
    Wei Sheng Yan Jiu; 2012 Mar; 41(2):251-6. PubMed ID: 22611936
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genetic polymorphisms in cell cycle regulatory genes MDM2 and TP53 are associated with susceptibility to lung cancer.
    Zhang X; Miao X; Guo Y; Tan W; Zhou Y; Sun T; Wang Y; Lin D
    Hum Mutat; 2006 Jan; 27(1):110-7. PubMed ID: 16287156
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Distribution of GSTM1, GSTT1, GSTP1 and TP53 disease-associated gene variants in native and urban Venezuelan populations.
    Chiurillo MA; Griman P; Santiago L; Torres K; Moran Y; Borjas L
    Gene; 2013 Nov; 531(1):106-11. PubMed ID: 23994684
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genetic polymorphisms and susceptibility to childhood acute lymphoblastic leukemia.
    Canalle R; Burim RV; Tone LG; Takahashi CS
    Environ Mol Mutagen; 2004; 43(2):100-9. PubMed ID: 14991750
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Glutathione S-transferase M1, T1, and P1 polymorphisms and survival among lung cancer patients.
    Sweeney C; Nazar-Stewart V; Stapleton PL; Eaton DL; Vaughan TL
    Cancer Epidemiol Biomarkers Prev; 2003 Jun; 12(6):527-33. PubMed ID: 12814998
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of GSTP1 Ile105Val and XRCC1 Arg194Trp, Arg280His and Arg399Gln gene polymorphisms in the clinical outcome of advanced non-small cell lung cancer.
    Zhao R; Chen G
    Int J Clin Exp Pathol; 2015; 8(11):14909-16. PubMed ID: 26823821
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Polymorphisms in detoxification genes CYP1A1, CYP2E1, GSTT1 and GSTM1 in gastric cancer susceptibility].
    González A; Ramírez V; Cuenca P; Sierra R
    Rev Biol Trop; 2004 Sep; 52(3):591-600. PubMed ID: 17361553
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of genetic predisposition on the risk of gallbladder cancer in Hungary.
    Kimura A; Tsuchiya Y; Lang I; Zoltan S; Nakadaira H; Ajioka Y; Kiyohara C; Oyama M; Nakamura K
    Asian Pac J Cancer Prev; 2008; 9(3):391-6. PubMed ID: 18990008
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of glutathione S transferases P1 (Ile105Val) variants on the risk of GSTp, phosphorylated c-Jun kinase, and P53 phenotypic expression and their implications on overall survival outcomes in non-small cell lung cancer patients treated with chemotherapy.
    Pathak AK; Husain N; Shukla S; Pandey RK; Kant S; Bala L
    Mutat Res; 2022; 824():111775. PubMed ID: 35124341
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Glutathione S-transferase P1 polymorphism (Ile105Val) predicts cumulative neuropathy in patients receiving oxaliplatin-based chemotherapy.
    Lecomte T; Landi B; Beaune P; Laurent-Puig P; Loriot MA
    Clin Cancer Res; 2006 May; 12(10):3050-6. PubMed ID: 16707601
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.